The histological patterns exhibited in the endometrium due to the newer progestational agents cannot be correlated with the patient's menstrual cycle or the physiological endometrium which follows ovulation. The oral progestational agents which have been produced during the past few years have had wide clinical application. Although the 19-nor-steroids and the derivatives of 17 alphahydroxyprogesterone differ in chemical structure, they produce similar histological appearances in the endometrium. Prolonged use of these compounds produces atrophy of the endometrial glands and a cellular stroma which might be mistaken for endometrial sarcoma. In view of the fact that such compounds are widely used in clinical practice and as contraceptive agents, it is essential that the pathologist should be aware of the bizarre endometrial patterns which they may produce; the more important of these changes are illustrated and discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC480726 | PMC |
http://dx.doi.org/10.1136/jcp.17.3.205 | DOI Listing |
J Community Hosp Intern Med Perspect
November 2024
Department of Internal Medicine, HCA Healthcare, MountainView Hospital, 2880 N Tenaya Way, 89128, Las Vegas, NV, USA.
Paraneoplastic limbic encephalitis (PLE) is a poorly understood condition, thought to be caused by the cross-reacting of tumor antibodies with neurons in the brain, resulting in neuropsychiatric sequelae, such as personality and behavioral changes, psychosis, memory loss, and seizures. Anti-contactin-associated protein-like 2 (CASPR2) antibodies can cause PLE in patients with particular tumors, which in most cases can be identified as thymoma, lung cancer, or endometrial cancer. Some case reports show rare instances with other tumors, such as throat or sigmoid carcinoma.
View Article and Find Full Text PDFObjectives: To assess if ProMisE classifier molecular subtypes are associated with differing survival outcomes in uterine carcinosarcoma (UCS) and compare these outcomes to endometrioid endometrial cancer (EEC) tumors.
Methods: There were 2235 UCS and 6469 EEC tumors using next-generation sequencing of DNA, whole exome sequencing, and RNA. Microsatellite instability (MSI) was tested by IHC and NGS.
Virchows Arch
January 2025
Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Low-grade endometrial stromal sarcoma (LG-ESS) can present diagnostic challenges, due to its overlapping morphological features with other uterine mesenchymal tumors. Misdiagnosis rates remain significant, and immunohistochemical data for LG-ESS are limited to small series and inconsistent antibody panels. This study aimed to refine the IHC profile of LG-ESS by analyzing a large, molecularly confirmed series of 147 cases using a panel of 24 antibodies, including newer markers like transgelin and smoothelin.
View Article and Find Full Text PDFHereditas
January 2025
Department of Gynaecology and Obstetrics, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, Sichuan, China.
Background: Uterine Corpus Endometrial Carcinoma (UCEC) is a prevalent gynecologic malignancy with complex molecular underpinnings. This study identifies key woundhealing genes involved in UCEC and elucidates their roles through a comprehensive analysis.
Methods: In silico and in vitro experiments.
Int J Surg Case Rep
January 2025
Department of Gynecology-Obstetrics, Mohammed V Military University Hospital, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Introduction And Importance: Uterine arteriovenous malformations (UAVMs) are rare vascular anomalies caused by abnormal connections between uterine arteries and veins. They can lead to severe bleeding, requiring prompt and accurate diagnosis. Historically treated with hysterectomy, transcatheter vascular embolization has emerged as a fertility-sparing alternative.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!